Badih Elmunzer to Anti-Inflammatory Agents, Non-Steroidal
This is a "connection" page, showing publications Badih Elmunzer has written about Anti-Inflammatory Agents, Non-Steroidal.
Connection Strength
4.890
-
The Skyrocketing Cost of Rectal Indomethacin. JAMA Intern Med. 2020 05 01; 180(5):631-632.
Score: 0.584
-
How to Avoid Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Gastrointest Endosc Clin N Am. 2018 Oct; 28(4):439-454.
Score: 0.523
-
Reducing the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. Dig Endosc. 2017 Nov; 29(7):749-757.
Score: 0.482
-
Should We Still Administer Prophylactic Rectal NSAIDs to?Average-Risk Patients Undergoing ERCP? Gastroenterology. 2016 09; 151(3):566-7.
Score: 0.450
-
Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP: study protocol for a randomized controlled trial. Trials. 2016 03 03; 17(1):120.
Score: 0.438
-
Nonsteroidal anti-inflammatory drugs for preventing post-ERCP pancreatitis: why rectal and not intramuscular? Endoscopy. 2015 Jan; 47(1):6-7.
Score: 0.403
-
Can rectal NSAIDs replace prophylactic pancreatic stent placement for the prevention of post-ERCP pancreatitis? Gastroenterology. 2014 Jan; 146(1):313-5; discussion 315.
Score: 0.374
-
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12; 366(15):1414-22.
Score: 0.334
-
A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008 Sep; 57(9):1262-7.
Score: 0.253
-
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 09; 6(9):733-742.
Score: 0.158
-
Real-World Practice Patterns in the Era of Rectal Indomethacin for Prophylaxis Against Post-ERCP Pancreatitis in a High-Risk Cohort. Am J Gastroenterol. 2020 06; 115(6):934-940.
Score: 0.147
-
Combination pharmacoprophylaxis for post-ERCP pancreatitis: working toward an evidence base. Gastrointest Endosc. 2017 05; 85(5):1014-1016.
Score: 0.119
-
Preventing Postendoscopic Retrograde Cholangiopancreatography Pancreatitis. Gastrointest Endosc Clin N Am. 2015 Oct; 25(4):725-36.
Score: 0.105
-
Evaluation of Pharmacologic Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Systematic Review. Clin Gastroenterol Hepatol. 2015 Jul; 13(7):1231-9; quiz e70-1.
Score: 0.101
-
The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. Gastrointest Endosc. 2015 Jan; 81(1):150-5.
Score: 0.101
-
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014. Endoscopy. 2014 Sep; 46(9):799-815.
Score: 0.098
-
Systematic review with network meta-analysis: pharmacological prophylaxis against post-ERCP pancreatitis. Aliment Pharmacol Ther. 2013 Dec; 38(11-12):1325-37.
Score: 0.093
-
Preventing pancreatitis after endoscopic retrograde cholangiopancreatography. Gastrointest Endosc Clin N Am. 2013 Oct; 23(4):769-86.
Score: 0.091
-
Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020 02; 5(2):132-141.
Score: 0.035